PrognomiQ, a healthcare company focused on harnessing multi-omics data to transform the detection and early treatment selection and monitoring of cancer and other complex diseases, announced early results from a large, deep multi-omics study, demonstrating the power of diverse molecular biomarkers to improve sensitivity and specificity in the early-stage detection of cancer.
The preliminary data stems from a 1,031-subject liquid biopsy study which compared the molecular biomarkers of non-small cell lung cancer (NSCLC) with non-cancer controls. The potential of the multi-omics markers to differentiate between cancer and controls catalyzed the launch of a 15,000-subject prospective clinical program, which has enrolled its first patient, initiating PrognomiQ’s next phase of product development.
“Early detection of cancer is incredibly complex and challenging, which is why we’re pleased with our product pipeline and preliminary data that supports further exploration of PrognomiQ’s liquid biopsy approach in lung, pancreatic and other cancers,” says Philip Ma, founder and CEO of PrognomiQ. “We are seeing strong performance for early-stage detection of non-small cell lung cancer, demonstrating the potential for PrognomiQ’s multi-omics methodology to transform liquid biopsy.”
PrognomiQ’s proprietary methodology interrogates the range of data from genotype to phenotype including cell-free DNA, RNA, proteins, metabolites, and lipids to identify potential biomarkers of significance. To analyze proteins, the company employs the Proteograph Product Suite from Seer, Inc. The combination of proteomic data with genomic, metabolomic, epigenomic, and transcriptomic data provides PrognomiQ with novel biological insights which could lead to transformative new approaches to diagnostic and therapy development.
“I’m excited about these early results in lung cancer, where there is such a high unmet need for earlier detection and treatment, and with PrognomiQ’s potential to transform the performance of liquid biopsies using a multi-omics approach for lung and other lethal cancers,” says Luis A. Diaz, head of the division of Solid Tumor Oncology in Memorial Sloan Kettering’s Department of Medicine as well as a pioneer in the liquid biopsy field and a member of Seer’s Scientific Advisory Board.
PrognomiQ is planning to submit the results from its large-scale multi-omics lung cancer study for publication later in 2023.